Arch Biopartners Management

Management criteria checks 2/4

Arch Biopartners' CEO is Richard Muruve, appointed in Aug 2009, has a tenure of 14.67 years. directly owns 15% of the company’s shares, worth CA$18.12M. The average tenure of the management team and the board of directors is 12.6 years and 14 years respectively.

Key information

Richard Muruve

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	14.7yrs
CEO ownership	15.0%
Management average tenure	12.6yrs
Board average tenure	14yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Richard Muruve's remuneration changed compared to Arch Biopartners's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CA$2m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$4m
Mar 31 2023	n/a	n/a	-CA$4m
Dec 31 2022	n/a	n/a	-CA$3m
Sep 30 2022	CA$113k	CA$113k	-CA$1m
Jun 30 2022	n/a	n/a	-CA$257k
Mar 31 2022	n/a	n/a	-CA$423k
Dec 31 2021	n/a	n/a	CA$308k
Sep 30 2021	CA$100k	CA$100k	-CA$1m
Jun 30 2021	n/a	n/a	-CA$3m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	n/a	n/a	-CA$6m
Sep 30 2020	CA$383k	CA$100k	-CA$5m
Jun 30 2020	n/a	n/a	-CA$4m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	n/a	n/a	-CA$2m
Sep 30 2019	CA$100k	CA$100k	-CA$2m
Jun 30 2019	n/a	n/a	-CA$2m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	n/a	n/a	-CA$3m
Sep 30 2018	CA$100k	CA$100k	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$2m
Dec 31 2017	n/a	n/a	-CA$2m
Sep 30 2017	CA$100k	CA$100k	-CA$2m

Compensation vs Market: Insufficient data to establish whether Richard's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.

CEO

Richard Muruve (52 yo)

14.7yrs

Tenure

CA$112,500

Compensation

Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and President since May 12, 2010. Mr. Muruve served as Acting Chief Financial...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Daniel Muruve	Co-Founder	12.6yrs	CA$289.00k	2.92% CA$ 3.5m
Andrew Bishop	CFO & Director	no data	CA$289.00k	0.76% CA$ 922.4k
Richard Muruve	Co-Founder	14.7yrs	CA$112.50k	15% CA$ 18.1m
Justin MacDonald	Co-Founder & Principal Scientist	no data	no data	no data
Paul Beck	Co-Founder & Principal Scientist	no data	no data	no data
Aaron Benson	Director of Communications	less than a year	no data	no data

12.6yrs

Average Tenure

Experienced Management: ARCH's management team is seasoned and experienced (12.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Daniel Muruve	Co-Founder	no data	CA$289.00k	2.92% CA$ 3.5m
Andrew Bishop	CFO & Director	14yrs	CA$289.00k	0.76% CA$ 922.4k
Richard Muruve	Co-Founder	18.7yrs	CA$112.50k	15% CA$ 18.1m
Claude Allary	Independent Director	10yrs	CA$289.00k	0.33% CA$ 397.8k
Richard Rossman	Independent Director	13.9yrs	no data	3.4% CA$ 4.1m
Robert Hodges	Member of Scientific Advisory Board	no data	no data	no data
Hindrik Mulder	Member of Scientific Advisory Board	no data	no data	no data

14.0yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ARCH's board of directors are seasoned and experienced ( 14 years average tenure).

Arch Biopartners Management

Management criteria checks 2/4

Key information

Recent management updates

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Insufficient new directors

Recent updates

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.035 loss in 1Q 2023)

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.008 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.003 loss in 1Q 2022)

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Insufficient new directors

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Third quarter 2021 earnings released: EPS CA$0.014 (vs CA$0.037 loss in 3Q 2020)

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

New 90-day low: CA$1.25

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

New 90-day low: CA$1.26

Full year 2020 earnings released: CA$0.077 loss per share (vs CA$0.036 loss in FY 2019)

New 90-day low: CA$1.37

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

New 90-day high: CA$1.56

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

New 90-day low - CA$1.24

Third quarter earnings released

New 90-day low - CA$1.25

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age